Prostate Cancer data Base Sweden (PCBaSe) is a nationwide population-based database that links the National Prostate Cancer Register (NPCR) of Sweden to other health care registries and demographic databases using the individually unique Swedish Personal Identity Number. PCBaSe 4.0 consists of more than 180,000 men on AEDs with comprehensive data on inpatient and outpatient care, prescription patterns, and socioeconomic factors [11 (link)]. Due to ethical considerations from the Swedish Board of Health and Welfare, age in PCBaSe is not captured more precisely than by year of birth and quarter of birth year.
All new PCa cases diagnosed between 2014 and 2016 were extracted from PCBaSe. The date of PCa diagnosis was used as the index date for cases and their respective controls. Each PCa case in this study was matched to five controls by their year of birth and residency. The five controls per case were selected from the general Swedish population and were free of PCa on the date of diagnosis for the corresponding case, lived in the same county, and had the same year of birth. Exposure was defined from filled prescription date for any AED in the Prescribed Drug Registry (within a fixed exposure window of 8.5 years) for all cases and controls. The AEDs included in the final analysis were sodium valproate (Anatomical Therapeutic Chemical (ATC) code: N03AG01), carbamazepine (ATC code: N03AF01), lamotrigine (ATC code: N03AX09), levetiracetam (ATC code: N03AX14), oxcarbazepine (ATC code: N03AF02), ethosuximide (ATC code: N03AD01), topiramate (ATC code: N03AX11), phenytoin (ATC code: N03AB02), gabapentin (ATC code: N03AX16), pregabalin (ATC code), clonazepam (ATC code: N03AX14), primidone (ATC code: N03AA03), phenobarbital (ATC code: N03AA02), lacosamide (ATC code: N03AX18), zonisamide (ATC code: N03AX15), and eslicarbazepine (ATC code: N03AF04). Sodium valproate, lamotrigine, levetiracetam, oxcarbazepine, and topiramate were AEDs with known HDACi properties.
All new PCa cases diagnosed between 2014 and 2016 were extracted from PCBaSe. The date of PCa diagnosis was used as the index date for cases and their respective controls. Each PCa case in this study was matched to five controls by their year of birth and residency. The five controls per case were selected from the general Swedish population and were free of PCa on the date of diagnosis for the corresponding case, lived in the same county, and had the same year of birth. Exposure was defined from filled prescription date for any AED in the Prescribed Drug Registry (within a fixed exposure window of 8.5 years) for all cases and controls. The AEDs included in the final analysis were sodium valproate (Anatomical Therapeutic Chemical (ATC) code: N03AG01), carbamazepine (ATC code: N03AF01), lamotrigine (ATC code: N03AX09), levetiracetam (ATC code: N03AX14), oxcarbazepine (ATC code: N03AF02), ethosuximide (ATC code: N03AD01), topiramate (ATC code: N03AX11), phenytoin (ATC code: N03AB02), gabapentin (ATC code: N03AX16), pregabalin (ATC code), clonazepam (ATC code: N03AX14), primidone (ATC code: N03AA03), phenobarbital (ATC code: N03AA02), lacosamide (ATC code: N03AX18), zonisamide (ATC code: N03AX15), and eslicarbazepine (ATC code: N03AF04). Sodium valproate, lamotrigine, levetiracetam, oxcarbazepine, and topiramate were AEDs with known HDACi properties.
Free full text: Click here
